Bloomberg Billionaires Index

View profiles for each of the world’s 500 richest people, see the biggest movers, and compare fortunes or track returns.

# 128 Thomas Struengmann $13.9B

Random fact: Business partner Andreas Strungmann is his identical twin.


Strungmann and his brother Andreas sold two pharmaceutical companies for 5.7 billion euros ($7.5 billion) in 2005. The pair sold drugmaker Hexal as well as their 68% stake in affiliate EON Labs. The siblings, who shared the proceeds equally, invest in companies through Zurich-based Santo Holding and Munich-based Athos.

As of :
Last change +$59.8M ( +0.4%)
YTD change -$91.3M ( -0.7%)
Biggest asset BNTX US Equity
Country / Region Germany
Age 73
Industry Health Care
View net worth over:   Max 1 year 1 quarter 1 month 1 week

Relative Value

Thomas Struengmann's net worth of $13.9B can buy ...

troy ounces of gold
barrels of crude oil

... and is equivalent to ...

of the GDP of the United States
of the total wealth of the 500 richest people in the world
of the top 100 U.S. college endowments
of the top 200 U.S. executives’ total awarded compensation
of U.S. existing home sales
times the median U.S. household income

Latest News

Net Worth Summary

Private asset
Public asset
Misc. liabilities
Confidence rating:

Strungmann's wealth derives from his half share of the proceeds from the sale of two pharmaceutical companies in 2005. Strungmann and his brother Andreas raised 5.7 billion euros ($7.5 billion) from the sale of generic drug maker Hexal and their 68% stake in Hexal's affiliate EON Labs.

The brothers jointly own stakes in publicly traded biotech firms. The biggest is their stake in BionTech, a company involved in the production of a Covid-19 vaccine. They own about 43% of the company based on the stake disclosed in a February 2022 regulatory filing. They also hold about 70% of 4SC, 6.1% of Tonies and 1.6% of Certara.

The value of his cash investments has been adjusted based on an analysis of dividends, taxes and market performance, and includes his share of assets held in trust by Munich-based investment firm Athos.

Some of the proceeds from the sale were used to invest in startup companies through Santo Holding, which doesn't disclose financials. The Zurich-based group is valued based on the equity value of its Holzkirchen, Germany-based major subsidiary Santo Holding (Deutschland), which is published annually on the German Federal Gazette.

Santo and Athos are owned by the brothers' families, and their assets are attributed to Thomas and Andreas in this analysis to reflect their roles as heads of their family.

Hanspeter Burkhart, a spokesman for Santo Holding in Zurich, didn't respond to messages seeking comment.


Family: Unknown, No children

Strungmann was born in 1950 with his identical twin brother, Andreas. Both brothers obtained doctorates, Thomas in economics and Andreas in medicine.

Thomas and Andreas joined the family business Durachemie in 1979, working with their father Ernst who started it 10 years earlier. After selling the company in 1986, the brothers started Hexal, which they built into one of the world's biggest generic drug companies, according to the Ernst Strungmann Institute website.

Hexal was sold in 2005 to publicly traded pharmaceutical company Novartis. The brothers also off loaded their two-thirds stake in US generic drug company Eon Labs. The sales generated 5.7 billion euros ($7.5 billion) in cash for the brothers.

The brothers continued to work in partnership following the sales and invested more than 500 million euros in German biotechnology companies. Thomas told Germany's Manager Magazin in 2008 that he and his brother were planning to create something similar to Hexal.

In the same year, the brothers gave 200 million euros ($220 million) to establish neuroscience research group, the Ernst Strungmann Institute. It's fully-funded by the pair and named after their father.

Both brothers live near Munich.

  • 1950 Identical twins Andreas and Thomas Strungmann are born.
  • 1969 Ernst Strungmann enters the generic drug business.
  • 1979 Joins family business alongside father Ernst.
  • 1986 Ernst sells his company to rival Cyanamid Lederle.
  • 2005 Ernst Strungmann dies.
  • 2005 Raises 5.7 billion euros from Hexal and Eon Labs sales.
  • 2008 Thomas and Andreas establish Ernst Strungmann Institute.
  • 2008 Plans to invest 500 million euros in German biotech companies.